Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.59 |
| ▸ | CA1 | P00915 | 2/20 | 0.59 |
| ▸ | CA2 | P00918 | 2/20 | 0.59 |
| ▸ | CA9 | Q16790 | 2/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.54 |
| ▸ | GRM5 | P41594 | 4/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | HAO1 | Q9UJM8 | 2/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30707880 | 0.85 | GRM5 (0.66) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL6132140 | 0.85 | GRM5 (0.66) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL15014349 | 0.84 | APP (0.66) | CA12CA1CA2CA9APP | |
| SCHEMBL27952694 | 0.82 | GRM5 (0.55) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL702612 | 0.82 | CA12 (0.66) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL4267103 | 0.80 | CA12 (0.63) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL4528239 | 0.79 | APP (0.59) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL13335288 | 0.79 | CA12 (0.62) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL24434459 | 0.78 | GRM5 (0.54) | CA12CA1CA2CA9FFAR1 | |
| SCHEMBL2869132 | 0.77 | CA12 (0.56) | CA12CA1CA2CA9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | BioMendics, LLC (US) | 2022-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | LMAN1, DPM1, DSTN | CA12 4823/4885CA1 4803/4885CA2 4202/4885 |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | CA12 4823/4885CA1 4803/4885CA2 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.